UpdatesGeneral Updates
Morepen Labs invested ₹20 Cr in its wholly-owned pharma subsidiary, Morepen RX Ltd, via a rights issue.
Morepen Laboratories LimitedMOREPENLAB · Filed with the exchange
This capital infusion strengthens MRX's base and supports its branded Rx products business.
MRX reported a FY26 turnover of ₹54.49 Cr.
No comments yet. Be the first.